Haemostasis Articles & Analysis
26 news found
The infrared coagulator, a spin off of laser technology, has been used for more than a decade, first in Europe and then in the United States, for the in-office elimination offlrst and second degree hemorrhoids. Even more recently, it has been employed in the treatment and removal of unwanted tattoos. This device has been FDA approved for both anorectal and dermatologic applications. Within the ...
Entegrion Announces CE Mark for Point of Care System for Blood Coagulation Monitoring. Regulatory clearance makes Entegrion’s innovative point of care diagnostic instrument for viscoelastic coagulation testing available to clinicians in Europe. DURHAM, N.C. (PRWEB) January 19, 2018 — Entegrion, Inc. today announced that it has achieved CE mark for the Company’s portable ...
Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced two publications that evaluated the Embrace™ Hydrogel Embolic System (HES) in preclinical porcine hemorrhage models. In a Journal of Vascular and Interventional Radiology (JVIR) publication, Dr. Gandras et al. evaluated[i] the ability of Embrace HES to ...
The good news for his patient was that she was young. A lower extremity bypass procedure - like any surgery - can be more difficult as we age. The bad news was that the best veins for the procedure - which involves grafting a vein from another part of the body to bypass her blocked arteries in the leg - were unusable. The patient had undergone varicose vein treatments as a young woman that ...
Podium presentation highlights significant transduction and transgene expression in pharmacokinetic studies in mice, non-human primates and a humanized liver model Poster presentation focuses on pharmacology, toxicology and safety studies Poster presentation focuses on the development of a novel transduction assay to evaluate in-vitro relative Infectivity ASC Therapeutics, a privately held ...
As a specialist in its field, Stago has introduced this new MyOptiLab service, designed for both current and future users of Stago solutions, to augment the expertise of haemostasis laboratories. The company will be placing over 35 experts in Lean Six Sigma methodologies – its Lean Stago ambassadors – at the service of laboratories worldwide. ...
Cellphire Therapeutics, Inc., a biotechnology company developing next-generation allogeneic cellular therapeutics for application across multiple medical indications, announced today the appointment of Pamela B. Conley, Ph.D. to the company’s Board of Directors. “Pam is a terrific addition to our Board,” said Mike Gaffney, Chief Executive Officer. “Her work leading the ...
Objectives Highlighting the need for action Increasing global awareness Empowering people to seek immediate medical attention Advocating for "systems of care" to prevent, diagnose and treat patients appropriately History Founded in 2014 by the International Society on Thrombosis and Haemostasis (ISTH), the WTD is led by a global scientific steering committee. ...
Abram Scientific today announced it has secured a $2.9 million US Army Grant in support of the company’s effort to address the COVID-19 pandemic. This grant supports the clinical development of the CoagCare System to screen for COVID-19 related blood clotting disorders or coagulopathies in patients. The CoagCare System is intended to aid in the evaluation of clotting disorders and help ...
Abram Scientific today announced it has secured a $2.9 million US Army Grant in support of the company’s effort to address the COVID-19 pandemic. This grant supports the clinical development of the CoagCare System to screen for COVID-19 related blood clotting disorders or coagulopathies in patients. The CoagCare System is intended to aid in the evaluation of clotting disorders and help ...
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has received approval from the U.S. Food and Drug Administration for its Investigational Device Exemption application for its vascular sealant. The approval is the most recent validation of TISSIUM’s efforts to develop a unique platform of proprietary ...
ByTISSIUM
Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today a partnership with GC Pharma (KRX: 006280), a South Korean biopharmaceutical company formerly known as Green Cross Corporation, to discover and develop novel hemophilia therapies. GC Pharma is a pioneer in vaccines and protein therapeutics and has long been dedicated to research and ...
Endomedix announced today that it received a patent of 30 issued claims for its PLEXimine™ Polysaccharide Technology platform for a new class of biomaterials. The patent, “Methods and Compositions for Achieving Hemostasis and Stable Clot Formation”, also covers design features and mechanisms of action for its first product based on the technology. This technology platform ...
Revenue increases 13.6% (9.2% cc) as a result of the sustainable growth strategy, with advances in all divisions and regions Bioscience leads the growth with EUR 3,994 million of revenue (13.6%; 8.9% cc). Diagnostic and Hospital continue to make progress with sales of EUR 734 million (4.5%; 1.1% cc) and EUR 134 million (12.5%; 12.1% cc), respectively. Bio Supplies achieves EUR 267 million in ...
Microcatheter-delivered device designed to provide rapid and focal occlusion of a wide range of peripheral arterial targets Aliso Viejo, CA – November 4, 2019 – Okami Medical Inc., a medical device company, today announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and initial launch of the LOBO™ Vascular Occlusion System. The Company further announced ...
Santa Clara, Calif. - October 30, 2019 - Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced that positive results from the AMBULATE pivotal study demonstrating the safety and efficacy of the company’s VASCADE® MVP Venous Vascular Closure System compared to manual compression were published online in the Journal of the American College of Cardiology: ...
Endomedix, Inc., today announced that it will present its patented revolutionary technology to control bleeding in battlefield injuries at the upcoming Military Health System and Research Symposium (MHSRS) annual meeting. Loss of blood still remains the most common cause of potentially preventable deaths in battlefield casualties, two-thirds of such deaths result from truncal hemorrhage that ...
Endomedix, Inc., a developer of unique biosurgical products based on natural biopolymer systems, today announced it will provide the first public presentation of its work at a scientific meeting. The 2019 Annual Meeting is scheduled for April 3-6 in Seattle, Washington. The presentation will provide data and descriptions of the performance of its patented hydrogel biomaterial in a series of ...
VASCADE MVP is the first vessel closure technology designed for electrophysiology procedures – and proven by electrophysiology physicians in a multi-center, randomized, controlled clinical trial. Potential procedures include cardiac ablation and left atrial appendage closure among others. Greater than 400,000 patients per year in the United States may benefit – with procedures ...
Endomedix, Inc., a developer of unique biosurgical products based on its natural biopolymer systems, today announced that it has submitted a comprehensive patent application to protect both its latest chemistry technology and also the design and function of the spray-on hydrogel hemostat that it is developing for brain and spine surgery indications. This patent application further expands and ...